I topped up today. Imo , very undervalued Fully funded Cash generating company Superior technology and partnership with big biotech companies .We just need Patience
Because of the company’s technology, imo it may attract institutional investors to invest long term. This is still undervalued if we compare it to Avacta.
This is very undervalued . Neutralising antibodies as well being therapeutic is better than vaccines. Fab only needs partnership with the big pharma to develop this neutralising anitibodies. Dyor
It is only Novacyt in Aim with projected profit after of more than £100 billion Year end. The markey value should be at least £1 billion. Squeeze the shorters!